NEW YORK (GenomeWeb) – Genetic testing laboratory Pathway Genomics today announced a partnership with the Prospective Registry of Multiplex Testing, an online registry for patients who have undergone testing for cancer-causing genetic mutations.
PROMPT is a consortium of physicians and scientists at academic centers including Memorial Sloan-Kettering Cancer Center, the Mayo Clinic, the Abramson Cancer Center of the University of Pennsylvania, and the Dana-Farber Cancer Institute. The goal of the registry is to provide data that will be used to better understand the level of cancer risk associated with particular genes and evaluate clinical outcomes following testing for panels of those genes.
Pathway Genomics joins Ambry Genetics, GeneDx, Quest, and Myriad Genetics as partners in the project, which was announced in September.
"We are honored to collaborate with the country's leading cancer experts to help advance the understanding of cancer risk, the genes associated with it, and take steps to end preventable hereditary cancers," David Becker, CSO of Pathway Genomics, said in a statement.
"The PROMPT team welcomes Pathway Genomics to the group seeking to improve our understanding of mutations in genes other than BRCA1 and BRCA2," Mark Robson, co-founder of PROMPT and director of clinical genetics service at Memorial Sloan-Kettering, said.
The San Diego-based CLIA and CAP accredited laboratory will provide information about the PROMPT registry site to patients and healthcare providers receiving test results from panels of cancer-associated genes.
Pathway Genomics' testing services cover a variety of conditions including cancer risk, cardiac health, and inherited diseases, as well as aspects of personalized medicine.